Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients

  • Review Article
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

Mycophenolate mofetil (MMF), an ester prodrug of mycophenolic acid (MPA), is widely used as a maintenance immunosuppressive regimen in solid organ transplant patients. It is increasingly used for the prophylaxis and treatment of graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT) patients. MPA displays extensive binding to serum albumin and glucuronidation to the inactive MPA-7-O-glucuronide (MPAG). Here, we review and discuss the pertinent information regarding the clinical pharmacokinetics of MPA in HSCT patients. The pharmacokinetics of MPA are altered in HSCT patients with lower oral bioavailability, shorter half-life and higher clearance than those in healthy volunteers and renal transplant recipients. Moreover, clearance may be increased in young pediatric patients. The optimal MMF dosing and preferred targets are still under investigation in HSCT patients due to the substantial intra- and inter-individual pharmacokinetic variability of MPA and broad range of transplants (malignant vs. nonmalignant, related vs. unrelated donor, and human leukocyte antigen mismatch). The complex pharmacokinetics of MPA have partly hampered the efficient use of MMF, and pharmacokinetic studies in HSCT patients have been limited in size and mostly inconclusive. Future research should be multi-institutional and focus on developing clinical decisions with adequate statistical power to improve clinical care of HSCT recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995;17(6):681–4.

    Article  CAS  PubMed  Google Scholar 

  2. Kiehl MG, Shipkova M, Basara N, Blau IW, Schutz E, Armstrong VW, et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem. 2000;33(3):203–8.

    Article  CAS  PubMed  Google Scholar 

  3. Minagawa K, Yamamori M, Katayama Y, Matsui T. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. Int J Hematol. 2012;96(1):10–25.

    Article  CAS  PubMed  Google Scholar 

  4. Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, et al. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan. Clin Transplant. 2014;28(9):980–9.

    Article  CAS  PubMed  Google Scholar 

  5. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429–55.

    Article  CAS  PubMed  Google Scholar 

  7. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28(2):145–54.

    Article  PubMed  Google Scholar 

  8. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol. 2007;2(5):1062–72.

    Article  CAS  PubMed  Google Scholar 

  9. Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol. 2007;2(1):184–91.

    Article  CAS  PubMed  Google Scholar 

  10. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem. 1998;31(5):317–22.

    Article  CAS  PubMed  Google Scholar 

  11. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58.

    Article  CAS  PubMed  Google Scholar 

  12. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36(4):315–24.

    Article  CAS  PubMed  Google Scholar 

  13. Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014;24(1):73–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y, et al. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol. 2008;65(6):893–907.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jacobson P, El-Massah SF, Rogosheske J, Kerr A, Long-Boyle J, DeFor T, et al. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(2):113–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. van Hest RM, Doorduijn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M, et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit. 2007;29(3):353–60.

    Article  PubMed  Google Scholar 

  17. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):495–505.

    Article  CAS  PubMed  Google Scholar 

  18. McCune JS, Jacobson P, Wiseman A, Militano O. Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. Bone Marrow Transplant. 2015;50(2):165–72.

    Article  CAS  PubMed  Google Scholar 

  19. Borrows R, Chusney G, Loucaidou M, James A, Van Tromp J, Cairns T, et al. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation. Ther Drug Monit. 2007;29(1):122–6.

    Article  CAS  PubMed  Google Scholar 

  20. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5(5):987–94.

    Article  CAS  PubMed  Google Scholar 

  21. Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T, et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol. 2007;47(1):6–12.

    Article  CAS  PubMed  Google Scholar 

  22. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999;67(4):499–504.

    Article  CAS  PubMed  Google Scholar 

  23. Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005;78(5):486–500.

    Article  CAS  PubMed  Google Scholar 

  24. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005;106(13):4381–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol. 2001;52(5):605–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol pathol. 1995;23(2):115–23.

  27. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet. 1984;9(Suppl 1):10–7.

    Article  CAS  PubMed  Google Scholar 

  28. de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, et al. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. Ther Drug Monit. 2010;32(5):606–14.

    Article  PubMed  Google Scholar 

  29. Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A, et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001;15(3):176–84.

    Article  CAS  PubMed  Google Scholar 

  30. Jacobson P, Huang J, Rydholm N, Tran M, Defor T, Tolar J, et al. Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). J Clin Pharmacol. 2008;48(4):485–94.

    Article  CAS  PubMed  Google Scholar 

  31. Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2010;16(3):421–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol. 2013;53(4):393–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zeng L, Blair EY, Nath CE, Shaw PJ, Earl JW, Stephen K, et al. Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. Br J Clin Pharmacol. 2010;70(4):567–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kim H, Long-Boyle J, Rydholm N, Orchard PJ, Tolar J, Smith AR, et al. Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. J Clin Pharmacol. 2012;52(11):1665–75.

    Article  CAS  PubMed  Google Scholar 

  35. Frymoyer A, Verotta D, Jacobson P, Long-Boyle J. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol. 2013;75(2):463–75.

    Article  CAS  PubMed  Google Scholar 

  36. Downing HJ, Pirmohamed M, Beresford MW, Smyth RL. Paediatric use of mycophenolate mofetil. Br J Clin Pharmacol. 2013;75(1):45–59.

    Article  CAS  PubMed  Google Scholar 

  37. Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010;16(3):333–43.

    Article  CAS  PubMed  Google Scholar 

  38. Trevisan DD, Silva JB, Oliveira HC, Secoli SR, Lima MH. Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2015;75(2):393–400.

    Article  CAS  PubMed  Google Scholar 

  39. Glotzbecker B, Duncan C, Alyea E 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2012;18(7):989–1006.

    Article  CAS  PubMed  Google Scholar 

  40. Jaklic A, Collins CJ, Mrhar A, Sorror ML, Sandmaier BM, Bemer MJ, et al. High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther. 2013;51(9):711–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Li H, Mager DE, Sandmaier BM, Storer BE, Boeckh MJ, Bemer MJ, et al. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biol Blood Marrow Transplant. 2014;20(8):1121–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Naderer OJ, Dupuis RE, Heinzen EL, Wiwattanawongsa K, Johnson MW, Smith PC. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005;45(2):219–26.

    Article  CAS  PubMed  Google Scholar 

  43. Lam S, Partovi N, Ting LS, Ensom MH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother. 2008;42(7):1037–47.

    Article  CAS  PubMed  Google Scholar 

  44. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62(3):1060–7.

    Article  CAS  PubMed  Google Scholar 

  45. Rupprecht K, Schmidt C, Raspe A, Schweda F, Shipkova M, Fischer W, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196–201.

    Article  CAS  PubMed  Google Scholar 

  46. Royer B, Larosa F, Legrand F, Gerritsen-van Schieveen P, Berard M, Kantelip JP, et al. Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. Biol Blood Marrow Transplant. 2009;15(9):1134–9.

    Article  CAS  PubMed  Google Scholar 

  47. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2004;10(4):246–58.

    Article  CAS  PubMed  Google Scholar 

  48. Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T, et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2008;42(2):113–20.

    Article  CAS  PubMed  Google Scholar 

  49. Hiwarkar P, Shaw BE, Tredger JM, Brown NW, Kulkarni S, Saso R, et al. Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. Clin Transplant. 2011;25(2):222–7.

  50. Okamura A, Yamamori M, Shimoyama M, Kawano Y, Kawano H, Kawamori Y, et al. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2008;88(1):104–10.

    Article  CAS  PubMed  Google Scholar 

  51. Ng J, Rogosheske J, Barker J, Weisdorf D, Jacobson PA. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit. 2006;28(3):394–401.

    Article  CAS  PubMed  Google Scholar 

  52. McDermott CL, Sandmaier BM, Storer B, Li H, Mager DE, Boeckh MJ, et al. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1159–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Duffull SB, Wright DF, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses—a clinical viewpoint. Br J Clin Pharmacol. 2011;71(6):807–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Dong M, Fukuda T, Vinks AA. Optimization of mycophenolic acid therapy using clinical pharmacometrics. Drug Metab Pharmacokinet. 2014;29(1):4–11.

    Article  CAS  PubMed  Google Scholar 

  55. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4(12):2045–51.

    Article  CAS  PubMed  Google Scholar 

  56. Laverdiere I, Caron P, Couture F, Guillemette C, Levesque E. Liquid chromatography-coupled tandem mass spectrometry based assay to evaluate inosine-5′-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients. Anal Chem. 2012;84(1):216–23.

    Article  CAS  PubMed  Google Scholar 

  57. Fukuda T, Goebel J, Thogersen H, Maseck D, Cox S, Logan B, et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol. 2011;51(3):309–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, 1441 Moursund Street, Houston, TX, 77030, USA

    Daping Zhang & Diana S.-L. Chow

Authors
  1. Daping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana S.-L. Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daping Zhang.

Ethics declarations

Funding

No sources of funding were used to prepare this review.

Conflict of interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, D., Chow, D.SL. Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients. Eur J Drug Metab Pharmacokinet 42, 183–189 (2017). https://doi.org/10.1007/s13318-016-0378-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-016-0378-6

Keywords

Search

Navigation